![](https://endpts.com/wp-content/uploads/2023/04/Giovanni-Caforio-Bristol-Myers-Squibb-The-Galien-Foundation-feature.jpg)
Giovanni Caforio, Bristol Myers Squibb CEO (The Galien Foundation)
Bristol Myers makes a $4.8B bet on KRAS, striking deal to acquire Mirati
Bristol Myers Squibb has signed a $4.8 billion deal to buy Mirati Therapeutics and its cancer drug Krazati, which targets what …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.